Predictive value of PD-L1 and other clinical factors for chemoimmunotherapy in advanced non-small-cell lung cancer

Rachel Woodford, Yanni Loh, Joanna Lee, Wendy Cooper, Ian Marschner, Craig R. Lewis, Michael Millward, Sally Lord, Richard J. Gralla, James C.-H. Yang, Tony Mok, Chee K. Lee*

*Corresponding author for this work

    Research output: Contribution to journalReview articlepeer-review

    1 Citation (Scopus)

    Abstract

    We investigate if PD-L1 expression and other clinical characteristics predict chemoimmunotherapy (CIT) benefits versus chemotherapy in advanced non-small-cell lung cancer. We performed a meta-analysis of randomized controlled trials of CIT versus chemotherapy identified through electronic searches. In seven randomized controlled trials (n = 4170), CIT prolonged progression-free survival over chemotherapy (hazard ratio [HR]: 0.62; 95% CI: 0.58-0.67; p < 0.00001). The treatment benefits differed between PD-L1-high (HR: 0.41; 95% CI: 0.34-0.49) and PD-L1 low (HR: 0.63; 95% CI: 0.55-0.72; interaction-p = 0.00002) and PD-L1-high and PD-L1-negative (HR: 0.72; 95% CI: 0.65-0.80; interaction-p < 0.00001). Similar benefits were observed regardless of gender, EGFR/ALK status and histological subtype. PD-L1 status is predictive of CIT benefit and may assist patient selection and design of future trials.

    Original languageEnglish
    Pages (from-to)2371-2383
    Number of pages13
    JournalFuture Oncology
    Volume15
    Issue number20
    Early online date25 Jun 2019
    DOIs
    Publication statusPublished - Jul 2019

    Keywords

    • chemoimmunotherapy
    • meta-analysis
    • non-small-cell lung cancer
    • PD-L1 expression
    • progression-free survival

    Fingerprint

    Dive into the research topics of 'Predictive value of PD-L1 and other clinical factors for chemoimmunotherapy in advanced non-small-cell lung cancer'. Together they form a unique fingerprint.

    Cite this